



Constrained confidence partitioning. An innovative technique towards personalized drug treatment

Prof. Dr. Andreas Brieden¹ & Prof. Dr. Peter Gritzmann

GDSD 2022, LMU, Munich, July 14th, 2022

¹: Speaker



Overview

- I. Introduction
- II. Constrained Confidence Partitioning
- III. Prototypical Results
- IV. Conclusion

I. Introduction

Motivating question from medical science partners

- Can you identify (prototypes of) patients for that a specific treatment shows „significant“ different efficacy?
- In any case, a comprehensible (easy) explanation is mandatory!


Basic Idea

- After a suitable data transformation find such prototypes by an optimal partitioning of a high-dimensional geometric space.
- Do descriptive, predictive, or prescriptive analytics on the partition.

II. Constrained Confidence Partitioning


Detecting hidden data structures

- homogeneous clusters
- any dimension
- any number of clusters
- weighted points
- cardinality constraints
- „efficient running time“




Proximity measures and diagrams

- Proximity measures $\delta_i: 1 \leq i \leq k$
- Cluster definition $P_i := \{x \in \mathbb{R}^n: \delta_i(x) \leq \delta_l(x), 1 \leq l \leq k\}$



$$\delta_i(x) = \sqrt{(s_i - x)^T M_i (s_i - x)}$$



$$\delta_i(x) = (s_i - x)^T M_i (s_i - x)$$

s_i : (given) sites, M_i : sym. pos.-def. matrix


Convex Maximization (non pre-specified sites)

- Power diagram

$$\max \sum_{i=1}^k \sum_{j=1}^k \kappa_i \kappa_j \|c_i - c_j\|_2^2$$

$$\kappa_i^- \leq w(C_i) \leq \kappa_i^+, 1 \leq i \leq k$$

c_i : virtual center of gravity




$$\delta_i(x) = \|c_i - x\|_2^2$$

Power Diagram (weighted Voronoi diagram)

- control points $s_1, \dots, s_k \in \mathbb{R}^d$
- weights $w_1, \dots, w_k \in \mathbb{R}$
- Voronoi dissection:

Cell decomposition of \mathbb{R}^d into convex polyhedra P_1, \dots, P_k with

$$P_i = \left\{ x : j \neq i \implies \|s_i - x\|_2^2 - w_i \leq \|s_j - x\|_2^2 - w_j \right\}$$



Gravity polytope

- feasible partition V_1, \dots, V_k of points: $V_i \subseteq P_i, 1, \dots, k$
- gravity vector g_c of centers of gravity c_1, \dots, c_k :

$$g_c := \begin{pmatrix} c_1 \\ \vdots \\ c_k \end{pmatrix} \in \mathbb{R}^{dk}$$

- gravity polytope Q :
 $Q := \text{conv}(g_c : g_c \text{ is the gravity vector of a feasible partition})$

Results for the gravity polytope

- In the combinatorial case, each extremal clustering (i.e., a vertex of Q) admits a voronoi dissection.

Barnes, Hoffmann, Rothblum '92, Aurenhammer, Hoffmann, Aronov '98


Br. & Gritzmann '06, Borgwardt '10

- ...

- Solving $\max \sum \sum \kappa_i \kappa_j \|c_i - c_j\|_2^2$ corresponds to

Norm-Maximization over gravity polytopes.

Br. & Gritzmann '11




Complexity of Norm-Maximization over polytopes

- Approximation error of $\Theta(d / \log d)$ (in general)
Bárány & Füredi '89, Kochol '94
Br., Gritzmann, Kannan, Klee, Lovász & Simonovits (also for polynomial-time randomized algorithms)
- APX-hardness (even in special cases)
Br. '02
- Practical results much more promising!

II. Constrained Confidence Partitioning (revisited)

Detecting hidden data structures

- ✓ homogeneous clusters
- ✓ any dimension
- ✓ any number of clusters
- ✓ weighted points
- ✓ cardinality constraints
- ✓ „efficient running time“



Endpoint oriented data transformation

- General method

Discrete Radon Transformation (Discrete Tomography)

- Basic Application

axes parallel x-rays (conditional mean values)

$$\begin{pmatrix} \text{age} \\ \text{recent drug abuse} \\ \text{anxiety disorder} \\ \vdots \end{pmatrix} \longrightarrow \begin{pmatrix} \text{survival time age} \\ \text{survival time recent drug abuse} \\ \text{survival time anxiety disorder} \\ \vdots \end{pmatrix} \in \mathbb{R}^d$$

Sometimes necessary: binning & variable selection



III. Prototypical Results

- a. From industry: „Hiring bias (?)“
- b. From science: New insight into the Catie study

„Hiring bias (?)“

- Baseline:

Results from multinational randomized control trials do not show overall evidence (only in Europe) for higher efficacy of new drug compared to placebo.

This is in contrast to expert knowledge from „real-life treatment“ .

- Crucial pairs of patient prototypes detected by c^2p :

groups HP and HV with high response rate, HP getting placebo, HV verum

groups LP and LV with low response rate, LP getting placebo, LV verum

Crucial Prototypes

- HV:
not surprising
- HP:
mainly young male Americans
- LV:
mainly „lost to follow ups“ with „last observation carried forward“
mainly young male Americans
- LP:
not surprising

A possible explanation (from our partners)

- HP:
 „If I am paid, I have to perform!“
- LV:
 „My doctor does not know me and
 it is not enough money!“



MASSACHUSETTS GENERAL HOSPITAL
 HARVARD MEDICAL SCHOOL

Are you a daily cigarette smoker NOT planning to quit in the next 6 months?

And:

- ✓ Have ever had Anxiety, Depression OR PTSD
- ✓ Are willing to use different cigarettes than your usual brand
- ✓ Are ages 18-65

You might qualify for a research study at MGH to receive research cigarettes for 20 weeks at no cost, compensation of up to \$1000 and free parking at MGH

Contact us:
 617-643-5926

mghcam@mgh.harvard.edu
www.facebook.com/MGHCenterforAddictionMedicine

New insight into the CATIE study

- CATIE: **C**linical **A**ntipsychotic **T**rials of **I**ntervention **E**ffectiveness
- Should compare the effectiveness of older (first available in the 1950s) and newer (available since the 1990s) antipsychotic medications used to treat schizophrenia.
- Is known as the largest, longest (18 month), and most comprehensive independent trial ever done to examine existing therapies for schizophrenia.

Prototypical already known and new results

- Known: Clinical Antipsychotic Trials of Intervention Effectiveness
 - Olanzapine is superior to Ziprasidone
- New: Consider the following two prototypes:
 - noADH (No A) No anxiety disorder in the past month,
(No D) No drug abuse in the past 5 years, and
(No H) No hospitalization in the past year
 - ADH at least one of the above properties
 - Superiority of Olanzapine is even more distinct for group noADH,
but (very) questionable for ADH

Schiele, Br., Leucht & Heres '21

IV. Conclusion

- general approach
- delivers valuable, explainable insight into data
(especially by analyzing look-up tables)
- has successfully applied in many fields of application
(medicine, insurance, finance, logistics ...)

Final take away

